GILD Gilead Sciences, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

GILD [NASD]

Gilead Sciences, Inc.

Healthcare | Drug Manufacturers - General | USA

statements

Index	S&P 500	P/E	-	EPS (ttm)	-0.24	Insider Own	0.41%	Shs Outstand	1.26B	Perf Week	-0.92%
Market Cap	84.86B	Forward P/E	9.68	EPS next Y	7.04	Insider Trans	-1.19%	Shs Float	1.25B	Perf Month	-11.05%
Income	-257.00M	PEG	-	EPS next Q	1.98	Inst Own	82.40%	Short Float	1.77%	Perf Quarter	-11.72%
Sales	22.17B	P/S	3.83	EPS this Y	1.10%	Inst Trans	-0.31%	Short Ratio	2.27	Perf Half Y	2.07%
Book/sh	14.36	P/B	4.75	EPS next Y	0.79%	ROA	-0.40%	Target Price	80.17	Perf Year	8.02%
Cash/sh	15.20	P/C	4.49	EPS next 5Y	2.27%	ROE	-1.20%	52W Range	60.89 - 85.97	Perf YTD	4.92%
Dividend	2.72	P/FCF	16.40	EPS past 5Y	-10.50%	ROI	9.50%	52W High	-20.62%	Beta	0.62
Dividend %	3.99%	Quick Ratio	2.20	Sales past 5Y	-2.00%	Gross Margin	78.60%	52W Low	12.07%	ATR	1.56
Employees	11800	Current Ratio	2.30	Sales Q/Q	-9.50%	Oper. Margin	-4.30%	RSI (14)	35.30	Volatility	1.59% 2.04%
Optionable	Yes	Debt/Eq	1.34	EPS Q/Q	-280.70%	Profit Margin	-1.20%	Rel Volume	0.35	Prev Close	68.18
Shortable	Yes	LT Debt/Eq	1.17	Earnings	Jul 30 AMC	Payout	-	Avg Volume	9.71M	Price	68.24
Recom	2.50	SMA20	-5.51%	SMA50	-8.22%	SMA200	-4.46%	Volume	188,877	Change	0.09%

Jul-31-20

Reiterated

Wells Fargo

Equal Weight

$87 → $76

Jul-31-20

Reiterated

SunTrust

Hold

$73 → $74

Jul-31-20

Reiterated

RBC Capital Mkts

Outperform

$89 → $87

Jul-31-20

Reiterated

Piper Sandler

Overweight

$90 → $85

Jul-31-20

Reiterated

Morgan Stanley

Equal-Weight

$80 → $79

Jul-31-20

Reiterated

Credit Suisse

Neutral

$75 → $73

Jul-20-20

Upgrade

Credit Suisse

Underperform → Neutral

$64 → $75

Jun-03-20

Upgrade

SVB Leerink

Mkt Perform → Outperform

$85 → $94

May-26-20

Upgrade

SunTrust

Sell → Hold

$73

May-01-20

Downgrade

SunTrust

Hold → Sell

$70

May-01-20

Downgrade

Raymond James

Outperform → Mkt Perform

May-01-20

Downgrade

JP Morgan

Overweight → Neutral

Apr-27-20

Downgrade

UBS

Buy → Neutral

$77 → $80

Apr-20-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$87

Apr-20-20

Downgrade

BMO Capital Markets

Outperform → Market Perform

$79

Apr-17-20

Downgrade

CFRA

Hold → Sell

Mar-31-20

Initiated

Wolfe Research

Peer Perform

Mar-20-20

Upgrade

Piper Sandler

Neutral → Overweight

$70 → $90

Mar-18-20

Upgrade

DZ Bank

Hold → Buy

$80

Mar-09-20

Downgrade

RBC Capital Mkts

Top Pick → Outperform

$86

Aug-13-20 05:19PM	A Field Guide to Covid-19 Vaccines and Antivirals Barrons.com
12:16AM	Zydus Cadila launches India's cheapest remdesivir version at $37 per vial Reuters
Aug-12-20 02:35PM	CalPERS more than doubles Gilead and Zoom Video stakes, trims Apple and Microsoft MarketWatch
12:23PM	Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug Zacks
08:25AM	Is Diodes (NASDAQ:DIOD) Using Too Much Debt? Simply Wall St.
08:21AM	Is Now The Time To Look At Buying Diodes Incorporated (NASDAQ:DIOD)? Simply Wall St.
Aug-11-20 05:05PM	Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in August Reuters
10:28AM	India's shortage of remdesivir is easing, says producer Cipla Reuters
08:11AM	China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP) Business Wire
01:34AM	Gilead Seeks Full FDA Approval Of Its Remdesivir Drug For Coronavirus Benzinga
Aug-10-20 03:11PM	Gilead Sciences Submits New Drug Application for Remdesivir as a COVID-19 Treatment Motley Fool
02:33PM	Gilead Submits New Drug Application With FDA For Remdesivir SmarterAnalyst
11:55AM	Gilead Submits New-Drug Application for Remdesivir TheStreet.com
11:11AM	Gilead seeks U.S. approval for COVID-19 treatment remdesivir Reuters
11:06AM	Gilead files U.S. marketing application for remdesivir Reuters
11:00AM	Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19 Business Wire
08:38AM	5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism Zacks
07:06AM	Pfizer Inks Deal To Manufacture Gileads Covid-19 Remdesivir Treatment SmarterAnalyst
Aug-09-20 07:00AM	A Big Pension Bought GE, Merck, and Intel Stock. It Sold This Biotech. Barrons.com
Aug-07-20 04:23PM	These Chip Stocks Jumped On Upbeat Earnings Reports Investor's Business Daily
12:02PM	Pfizer to Produce Gilead Virus-Treatment Candidate Remdesivir TheStreet.com
11:04AM	Pfizer Will Help Gilead Sciences Make Its Covid-19 Treatment, Remdesivir Barrons.com
10:07AM	Pfizer, Gilead Strike Multiyear Partnership To Manufacture COVID-19 Drug Remdesivir Benzinga
09:11AM	NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment MarketWatch
08:10AM	Pfizer to help manufacture Gilead's remdesivir MarketWatch
08:07AM	Pfizer signs deal to supply Gilead's remdesivir for COVID-19 Reuters
04:00AM	UK's Hikma starts manufacturing COVID-19 treatment remdesivir for Gilead Reuters
Aug-06-20 04:05PM	Diodes Incorporated Reports Second Quarter 2020 Financial Results Business Wire
Aug-05-20 07:58AM	NIH to test Lilly's experimental monoclonal antibody treatment in mild and moderate COVID-19 cases MarketWatch
02:00AM	Zydus Cadila's COVID-19 vaccine candidate found safe in early-stage human trial Reuters
Aug-04-20 10:09PM	State attorneys general urge U.S. to let other firms make Gilead COVID-19 drug Reuters
01:35PM	NIH to launch trials to test antibody drugs for COVID-19 Reuters
11:45AM	State attorneys general urge U.S. govt to increase supply, lower price of remdesivir Reuters
06:41AM	Is Gilead Sciences a Buy After Its Disappointing Q2 Results? Motley Fool
04:26AM	Taiwan provisionally approves dexamethasone as coronavirus treatment Reuters
Aug-03-20 12:46PM	Gilead Stock Is Rising Because Covid-Treatment Sales Could Top $3 Billion Barrons.com
05:45AM	Rival drugmakers launch joint trial of medicines for COVID-19 Reuters
Aug-01-20 10:44AM	Better Buy: Gilead Sciences vs. Pfizer Motley Fool
01:33AM	Gilead Sciences (GILD) Q2 2020 Earnings Call Transcript Motley Fool
Jul-31-20 06:51PM	Remdesivir Maker Gilead Sciences Declares Dividend; Yield Is 3.9% Motley Fool
06:33PM	Merck to Begin Pivotal COVID-19 Antiviral Studies in September Motley Fool
04:43PM	Stocks Rise Amid Rally in Big Tech, Stimulus Talks: Markets Wrap Bloomberg
04:35PM	We need a national plan to bring us down to an agreed about level: doctor Yahoo Finance Video
04:31PM	Tech Giants Send Nasdaq Up 150+, but Coronavirus Vaccine Stocks Suffer on Gilead Earnings, Moderna Hack Attack Motley Fool
12:56PM	Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity Benzinga
11:35AM	Gilead (GILD) Misses on Q2 Earnings & Sales, Ups '20 Guidance Zacks
10:30AM	Gilead Remdesivir Output Outlook Draws Analyst's Skepticism TheStreet.com
08:45AM	US STOCKS-Pandemic boost for Big Tech set to drive Wall St higher Reuters
06:34AM	US STOCKS-Nasdaq futures jump as Big Tech booms during pandemic Reuters
Jul-30-20 11:31PM	Gilead raises sales outlook to include COVID-19 treatment remdesivir Reuters
07:28PM	Gilead Sciences' Revenue and Earnings Slip in Second Quarter Motley Fool
06:43PM	7 Biopharmaceutical Companies Finding Success During COVID-19 CorpGov.com
05:15PM	Gilead Sciences (GILD) Misses Q2 Earnings and Revenue Estimates Zacks
05:14PM	Gilead Shares Sink on Disappointing Earnings Barrons.com
04:28PM	Gilead swings to a big loss on acquisition expense, stock falls after earnings and revenue miss MarketWatch
04:11PM	Gilead reports quarterly loss on acquisition costs Reuters
04:02PM	Gilead Sciences Announces Third Quarter 2020 Dividend Business Wire
04:01PM	Gilead Sciences Announces Second Quarter and First Half 2020 Financial Results Business Wire
10:14AM	Precision Op Amp from Diodes Incorporated Features Ultra-Low Input Offset Voltage and Low Noise Business Wire
06:30AM	How a Biden Win Would Affect Different Market Sectorsand Stock Picks for Both Election Outcomes Barrons.com
Jul-29-20 05:21PM	U.S. Deaths Top 150,000; Records in Texas, Florida: Virus Update Bloomberg
04:28PM	Front Lines Against Coronavirus: Gilead, Moderna Prepare To Update Investors Benzinga
01:42PM	Gilead Sciences's Earnings Outlook Benzinga
12:25PM	Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More Zacks
09:27AM	4 Companies That Could Upend the Pharma Industry Motley Fool
07:00AM	Gilead Reports Earnings Tomorrow. Heres What to Expect. Barrons.com
06:11AM	RPT-EU executive signs remdesivir deal with Gilead Reuters
Jul-28-20 10:57AM	Canada gives conditional approval to Gilead's remdesivir for COVID-19 Reuters
09:00AM	Gilead Sciences and Satcher Health Leadership Institute at Morehouse School of Medicine Partner to Study Racial Health Inequities Associated with COVID-19 Business Wire
Jul-27-20 06:07PM	4 More Biotechs Break From IPO Starting Gate GuruFocus.com
02:50PM	Gilead Sciences Could Dip a Little in Reaction to Earnings TheStreet.com
01:31PM	Gilead CAR-t therapy receives FDA approval MarketWatch
03:38AM	By boat and on foot, Indian state hunts for plasma for COVID patients Reuters
Jul-26-20 08:16AM	Gileads Kite Gets FDA Nod For Tecartus Blood Cancer Treatment TipRanks
Jul-25-20 08:06AM	Is This Dark-Horse Coronavirus Stock a Threat to Gilead Sciences? Motley Fool
Jul-24-20 04:57PM	Trump signs executive order aimed at lowering drug prices Yahoo Finance Video
01:25PM	U.S. FDA Approves Kites Tecartus, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma Business Wire
01:12PM	Will Coronavirus Woes Impact Gilead's (GILD) Q2 Earnings? Zacks
11:38AM	Charting the Stocks of 3 Covid Treatment Companies TheStreet.com
08:49AM	The Further It Lags in the Vaccine Race, the Riskier Inovio Stock Looks InvestorPlace
08:33AM	EMA to review results from study testing common steroid drug against COVID-19 Reuters
08:10AM	Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis Business Wire
06:51AM	This Big Coronavirus Stock Offers Investors the Best Bang for the Buck Motley Fool
Jul-23-20 02:35PM	Biotech Stock Roundup: BIIB Reports Q2, GILD Acquires Stake in Private Company & More Zacks
12:32PM	Earnings Preview: Gilead Sciences (GILD) Q2 Earnings Expected to Decline Zacks
11:02AM	A Top Contender in the Race for a NASH Drug Drops Out Barrons.com
10:14AM	Diodes Incorporated Optimizes PNP Transistors for Automotive Matrix LED Lighting Business Wire
Jul-22-20 09:37AM	Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker Zacks
Jul-21-20 04:02PM	Gilead Sciences Invests $300 Million in an Immuno-Oncology Startup Motley Fool
01:21PM	The Parnassus Endeavor Fund Cuts Cisco, FedEx GuruFocus.com
10:00AM	Gilead Says Coronavirus Drug Lessens Death But Is GILD Stock A Buy? Investor's Business Daily
09:57AM	Gilead Pours $300M Into Tizonas Cancer Immunotherapy Pipeline SmarterAnalyst
08:43AM	Gilead Sciences to pay $300 million for nearly half of Tizona, has option to buy the rest for $1.25 billion MarketWatch
08:30AM	Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million Business Wire
08:24AM	Better Coronavirus Stock: Gilead Sciences or Novavax? Motley Fool
07:01AM	Better Buy: Amgen vs. Gilead Sciences Motley Fool
Jul-20-20 05:45PM	Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
12:25PM	Day Ahead: 3 Things to Watch for July 21 Investing.com
11:38AM	Credit Suisse Upgrades Gilead On Remdesivir Commercial Opportunity Benzinga
Jul-19-20 09:00AM	3 Top Coronavirus Stocks to Buy Right Now Motley Fool

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mercier Johanna	Chief Commercial Officer	Jul 24	Option Exercise	0.00	7,505	0	7,505	Jul 28 06:47 PM
Rodriguez Javier	Director	Jun 23	Sale	75.50	189	14,270	0	Jun 25 01:51 PM
Dickinson Andrew D	EVP, Chief Financial Officer	Jun 10	Option Exercise	0.00	3,646	0	15,046	Jun 12 03:28 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	May 05	Option Exercise	39.76	13,210	525,225	27,854	May 07 06:02 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	May 05	Sale	79.23	13,210	1,046,640	14,644	May 07 06:02 PM
Cogan John Francis	Director	May 04	Option Exercise	19.63	2,416	47,426	57,276	May 05 04:28 PM
Wilfong Diane E.	SVP, Controller & CAO	May 04	Option Exercise	66.36	11,486	762,211	23,685	May 06 06:40 PM
Wilfong Diane E.	SVP, Controller & CAO	May 04	Sale	80.09	12,264	982,220	11,421	May 06 06:40 PM
Cogan John Francis	Director	May 04	Sale	81.75	2,416	197,508	54,860	May 05 04:28 PM
Cogan John Francis	Director	Apr 27	Option Exercise	19.63	2,413	47,367	57,273	Apr 29 07:28 PM
Cogan John Francis	Director	Apr 27	Sale	79.90	2,413	192,799	54,860	Apr 29 07:28 PM
Cogan John Francis	Director	Apr 20	Option Exercise	19.63	2,413	47,367	57,273	Apr 21 07:42 PM
Cogan John Francis	Director	Apr 20	Sale	83.00	2,413	200,279	54,860	Apr 21 07:42 PM
Cogan John Francis	Director	Apr 13	Option Exercise	19.63	2,413	47,367	57,273	Apr 14 03:52 PM
Cogan John Francis	Director	Apr 13	Sale	75.90	2,413	183,147	54,860	Apr 14 03:52 PM
Cogan John Francis	Director	Apr 06	Option Exercise	19.63	2,413	47,367	57,273	Apr 07 05:34 PM
Cogan John Francis	Director	Apr 06	Sale	79.52	2,413	191,882	54,860	Apr 07 05:34 PM
Cogan John Francis	Director	Mar 30	Option Exercise	19.63	2,413	47,367	57,273	Mar 31 03:00 PM
Cogan John Francis	Director	Mar 30	Sale	75.35	2,413	181,820	54,860	Mar 31 03:00 PM
Cogan John Francis	Director	Mar 23	Option Exercise	19.63	2,413	47,367	57,273	Mar 24 08:42 PM
Cogan John Francis	Director	Mar 23	Sale	75.27	2,413	181,627	54,860	Mar 24 08:42 PM
Cogan John Francis	Director	Mar 16	Option Exercise	19.63	2,413	47,367	57,273	Mar 17 08:01 PM
Cogan John Francis	Director	Mar 16	Sale	67.26	2,413	162,298	54,860	Mar 17 08:01 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 10	Option Exercise	24.30	2,950	71,670	17,594	Mar 12 08:30 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 10	Sale	75.55	2,950	222,873	14,644	Mar 12 08:30 PM
Cogan John Francis	Director	Mar 09	Option Exercise	19.63	2,413	47,367	57,273	Mar 10 09:16 PM
Cogan John Francis	Director	Mar 09	Sale	77.97	2,413	188,142	54,860	Mar 10 09:16 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 02	Sale	70.88	10,441	740,014	14,644	Mar 03 07:40 PM
Lofton Kevin E	Director	Feb 24	Option Exercise	19.63	21,720	426,364	86,579	Feb 25 05:13 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 10	Option Exercise	24.30	2,950	71,670	27,640	Feb 12 06:25 PM
WILSON GAYLE E	Director	Feb 10	Option Exercise	19.63	21,720	426,364	148,502	Feb 11 07:02 PM
WILSON GAYLE E	Director	Feb 10	Sale	67.72	21,720	1,470,878	126,782	Feb 11 07:02 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 10	Sale	69.32	2,950	204,494	24,690	Feb 12 06:25 PM
WOLD OLSEN PER	Director	Feb 07	Option Exercise	20.65	20,282	418,722	118,136	Feb 10 06:25 PM
WOLD OLSEN PER	Director	Feb 07	Sale	69.00	20,282	1,399,458	97,854	Feb 10 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 07	Sale	70.00	1,426	99,820	24,690	Feb 10 07:00 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 06	Option Exercise	40.56	5,000	202,800	29,690	Feb 10 07:00 PM
WOLD OLSEN PER	Director	Feb 06	Option Exercise	19.63	21,720	426,364	119,574	Feb 10 06:25 PM
WOLD OLSEN PER	Director	Feb 06	Sale	68.12	21,720	1,479,605	97,854	Feb 10 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 06	Sale	68.18	5,000	340,901	24,690	Feb 10 07:00 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Jan 03	Option Exercise	24.30	2,950	71,670	20,014	Jan 06 07:01 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Jan 03	Sale	64.63	2,950	190,659	17,064	Jan 06 07:01 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Dec 03	Option Exercise	24.30	5,900	143,341	22,964	Dec 04 07:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Dec 03	Sale	65.77	5,900	388,043	17,064	Dec 04 07:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 25	Option Exercise	40.56	15,000	608,400	32,064	Nov 26 02:14 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 25	Sale	66.85	15,000	1,002,809	17,064	Nov 26 02:14 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 19	Option Exercise	24.30	10,000	242,950	27,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 19	Sale	64.91	10,000	649,062	17,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 18	Option Exercise	24.30	10,000	242,950	27,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 18	Sale	63.85	10,000	638,500	17,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 05	Sale	66.06	2,095	138,404	17,826	Nov 07 08:04 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 01	Option Exercise	16.89	2,400	40,536	23,921	Nov 05 08:21 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 01	Sale	64.52	4,000	258,099	19,921	Nov 05 08:21 PM
Pletcher Brett A	EVP, Gen Counsel & Corp Sec	Oct 28	Sale	63.31	5,677	359,412	21,521	Oct 30 08:35 PM
Lofton Kevin E	Director	Oct 01	Option Exercise	0.00	21,527	0	64,859	Oct 03 09:03 PM
WOLD OLSEN PER	Director	Aug 28	Option Exercise	23.76	4,908	116,590	102,762	Aug 29 04:42 PM
WOLD OLSEN PER	Director	Aug 28	Sale	63.91	4,908	313,671	97,854	Aug 29 04:42 PM
Pletcher Brett A	EVP, Gen Counsel & Corp Sec	Aug 19	Sale	64.35	608	39,123	27,198	Aug 20 03:13 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience